Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Zometa Side Effects Lawsuits | Side Effects: Femur Fractures, Esophageal Cancer, Osteonecrosis of the Jaw/Dead Jaw Syndrome, Atrial Fibrillation, Severe Musculoskeletal Pain

Zometa Side Effects May Be Linked To Femur Fracture Lawsuits

Zometa | Lawsuits, Lawyers | Side Effects: Femur Fractures, Esophageal Cancer, Osteonecrosis of the Jaw/Dead Jaw Syndrome, Atrial Fibrillation, Severe Musculoskeletal Pain

Our bisphosphonate lawyers are investigating injuries associated with this class of drugs. Bisphosphonates are sold under the names Actonel, Aredia, Bonefos, Boniva, Fosamax, Didronel, Reclast, Skelid and Zometa. Most people are familiar with these drugs as osteoporosis treatments for postmenopausal women. However, they are also approved for a variety of other indications, including other bone diseases such as Paget's disease. These drugs are also given to cancer patients for the prevention of fractures due to bone metastases.

Actonel, Boniva, Didronel, Fosamax and Skelid are all oral bisphosphonates. Aredia, Bonefos and Zometa are administered intravenously. Depending on which drug you are taking, and the condition for which you are being treated, bisphosphonates may be administered once per day, weekly, or monthly.

Over the past several years, bisphosphonates have been associated with a number of side effects, including:

  • Femur Fractures
  • Esophageal Cancer
  • Osteonecrosis of the Jaw/Dead Jaw Syndrome
  • Atrial Fibrillation
  • Severe Musculoskeletal Pain

If you or a loved one suffered one of these bisphosphonate side effects, you may be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages. Our bisphosphonate lawyers are currently offering free case evaluations to victims of these injuries. We urge you to contact us today to protect your legal rights.

Bisphosphonates and Osteonecrosis of the Jaw/Dead Jaw Syndrome

Osteonecrosis of the jaw (ONJ) or dead jaw syndrome is an excruciatingly painful and disfiguring bone disease. ONJ is a condition in which the bone tissue in the jaw fails to heal after minor trauma such as a tooth extraction, causing the bone to be exposed. The exposure can eventually lead to infection and fracture and may require long-term antibiotic therapy or surgery to remove the dying bone tissue.

An increased incidence of ONJ has been associated with the use of high dosages of bisphosphonates required by some cancer treatment regimens. The disease has also been seen in post-menopausal women taking the drugs for osteoporosis. Signs and symptoms of ONJ may include:  jaw pain, swelling of the gums, loose teeth, drainage, exposed jaw bone, numbness, or a feeling of heaviness in the jaw. 

Bisphosphonates and Esophageal Cancer

In September 2010, a study published in the British Medical Journal raised questions about a possible link between long-term use of bisphosphonates and cancer of the esophagus. The study involved an analysis of data from a nationwide medical practice research registry in the UK and followed about 90,000 people for 8 years. It included nearly 3,000 patients with esophageal cancer, 2,000 patients with stomach cancer, and 10,600 patients with colorectal cancer diagnosed between 1995 and 2005.

In people aged 60 to 70 who had 10 or more prescriptions for oral osteoporosis drugs for about 5 years, the study found the risk for developing esophageal cancer risk was 2 in 1,000. Normally, the risk of developing cancer of the esophagus, or throat, in people aged 60 to 79 is 1 in 1,000.

A year and a half prior to the publication of that study, the FDA reported that there had been 23 cases of the cancer in Fosamax users in the US between 1995 and 2008. Another 31 cases of the cancer were reported among bisphosphonate users in Europe and Japan. Since then, several more cases of esophageal cancer associated with bisphosphonate use have been reported to the FDA, bringing the total to 34.

Bisphosphonates and Atypical Femur Fractures

In 2010, the American Society of Bone and Mineral Research Femoral Fracture Task Force recommended that US health regulators rewrite the warning labels for bisphosphonates because of their possible association with atypical femur fractures. The task force recommendation was prompted by its finding that the bone drugs might be linked to the rare, but serious, type of thigh bone fracture. In conducting the study, the task force looked at 310 cases of atypical femur fractures and found that in the majority of cases (291), the patients had been taking bisphosphonates. The majority of patients had been taking the drugs for more than five years. Many of the patients were also taking glucocorticoids, which can lower bone density and increase fracture risks. The report noted that more than half of the patients studied experienced groin or thigh pain for a period of weeks or months before their fractures.

The previous March, the FDA announced it was reviewing bisphosphonates for a possible link to atypical subtrochanteric femur fractures in some patients who had been on the drugs for several years. Such fractures occur in the bone just below the hip joint and can be extremely painful. The FDA announced the review after two studies suggested bisphosphonates might adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years.

Bisphosphonates and Atrial Fibrillation

In 2008, a study conducted by researchers at the University of Washington found that treatment with Fosamax could double the risk of atrial fibrillation.  Atrial fibrillation – a chronic, irregular heartbeat – causes fatigue, dizziness and fainting, but it isn’t life-threatening.  Women who had taken the drug had an 86 percent higher risk of atrial fibrillation than those who never took Fosamax, the study found. But these results were far from conclusive, doctors say. Fosamax accounted for 3 percent of the atrial fibrillation cases, and 97 percent were the result of other causes. The researchers said their findings showed a need for more study on this potential Fosamax side effect.

A study published in 2007 in the May 7 issue of the New England Journal of Medicine also found that bisphosphonates appeared to increase the risk of irregular heartbeats in some older women. Researchers conducting a review of a 1997 study of postmenopausal women on bisphosphonates found that there appeared to be 50 percent more risk of the heart rhythm irregularity in women who took the drugs than among those who didn’t take it. About half of the 6,459 women took Fosamax, and 47 developed atrial fibrillation, compared to just 31 cases among the other women.

Bisphosphonates and Severe Musculoskeletal Pain

In January 2008, the FDA warned that use of bisphosphonates had been linked to severe and sometimes incapacitating bone, joint, and muscle (musculoskeletal) pain. The agency said it was concerned that the association between bisphosphonates and severe musculoskeletal pain may be overlooked by healthcare professionals, delaying diagnosis, prolonging pain and impairment, and necessitating the use of analgesics.

According to the FDA warning, the severe musculoskeletal pain associated with bisphosphonates may occur within days, months, or years after starting a bisphosphonate.  Some patients have reported complete relief of symptoms after discontinuing the bisphosphonate, whereas others have reported slow or incomplete resolution. The risk factors for and incidence of severe musculoskeletal pain associated with bisphosphonates are unknown.  The FDA recommended that healthcare professionals should consider whether bisphosphonate use might be responsible for severe musculoskeletal pain in patients who present with these symptoms and consider temporary or permanent discontinuation of the drug.

Legal Help for Victims of Bisphosphonate Injuries

If you or a loved one were treated with bisphosphonates and suffered any of the above injuries, you may have valuable legal rights. Please fill out our online form, or call 1-800-YOURLAWYER (1-800-968-7529) to discuss your case with one of our bisphosphonate lawyers today.

Novartis and the FDA notified dental healthcare professionals of revisions to the prescribing information about the occurrence of Osteonecrosis of the Jaw (ONJ) observed in cancer patients receiving treatment with intravenous bisphosphonates, including Zometa (generic: zoledronic acid). The FDA posted a letter from Swiss-based Novartis that was sent to dentists  warning of the problem. The letter also said patients should avoid invasive dental procedures while on the drug.

Officials from the FDA said they were concerned that many dentists and patients were not aware of the potential for jaw problems. The issue was discussed at an FDA advisory panel meeting in March 2005. Novartis said it had started studies to see if a link between the jaw problems and Zometa exists. At the time, Novartis officials said they had received 875 reports of osteonecrosis of the jaw from December 2002 through February 2005. Zometa was first put on the U.S. market in 2001 and had more than $1 billion in global sales. Zometa is used in the treatment of hypocalcaemia of malignancy, the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.

Osteonecrosis of the Jaw - ONJ

Osteonecrosis of the jaw (ONJ) has been reported in patients with cancer receiving treatment regimens including bisphosphonates. Many of these patients were also receiving chemotherapy and corticosteroids. The majority of reported cases have been associated with dental procedures such as tooth extraction. Many had signs of local infection including osteomyelitis. A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors (e.g. cancer, chemotherapy, corticosteroids, poor oral hygiene). ONJ is a complex problem with multiple risk factors. Typical signs and symptoms of ONJ include, but are not limited to: pain, swelling, or infection of the gums; loosening of the teeth; poor healing of the gums; numbness or a feeling of heaviness in the jaw; drainage and exposed bone. The seriousness of ONJ ranges from patient being asymptomatic to requiring sections of the jaw to be removed. Dentists, oral surgeons, periodontists, prosthodontists, dental hygienists, and other dental health professionals can play a vital role in identifying ONJ and other oral complications of cancer and cancer therapy.

Legal Help For Victims Affected By Zometa

If you or a loved one took Zometa and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).


ZometaRSS Feed

Study Finds Bisphosphonate Fracture Risk Increases with Longer Use

May 22, 2012 | Parker Waichman LLP
For the second time in a week, a new study is raising serious concerns about long-term use of Fosamax and other bisphosphonates.  The study, published in the Archives of Internal Medicine, confirmed a link between atypical thigh fractures and bisphosphonates, finding that the risk for such breaks increases the longer a patient uses the drugs.The study, conducted by doctors at the University Hospitals of Geneva in Switzerland, looked at records of 477 patients ages 50 years and older...

Bisphosphonates May be Less Effective in Preventing Fractures after Five Years

May 10, 2012 | Parker Waichman LLP
A new study published in the New England Journal of Medicine is raising new concerns about the efficacy of long-term bisphosphonate therapy.  The analysis, which was conducted by the U.S.  Food & Drug Administration (FDA), found that after about 3 to five years of use, bisphosphonates like Fosamax do little, if anything, to reduce the risk of fractures from osteoporosis.In conducting the bisphosphonate analysis, the FDA looked at two previously released studies that involved more...

Health Canada Revises Bisphosphonate Labels with Fracture Warning

Dec 20, 2011 | Parker Waichman LLP
Health Canada has announced that its review of bisphosphonates has shown a slightly increased risk of atypical thigh fractures among people who use these medications.  Bisphosphonates, a class of drugs used to treat osteoporosis, are sold in Canada under the brand names Fosamax, Fosavance, Didrocal, Actonel and Aclasta.   In the U.S., brand names bisphosphonates include Actonel, Aredia, Bonefos, Boniva, Fosamax, Didronel, Reclast, Skelid and Zometa.Canadian labels for or brand...

Bisphoshonate Benefits Plateau at Five Years, FDA Says

Sep 8, 2011 | Parker Waichman LLP
Women who take oral bisphosphonates such as Fosamax to prevent broken bones from osteoporosis may not have to take them beyond five years to get their full benefit, a new U.S. Food & Drug Administration (FDA) staff report says.  This is good news, considering some of the serious side effects that have recently been linked with long-term use of bisphosphonates, including a rare type of thigh fractures.The FDA staff report was released ahead of an advisory panel meeting that will take a...

Increased Vitamin D Might Make Bisphosphonates More Effective

Jun 9, 2011 | Parker Waichman LLP
Vitamin D supplementation might help bisphosphonates like Fosamax do a better job of protecting bones, a new study says.  The study, conducted by researchers at the Hospital for Special Surgery in New York, found that maintaining a circulating vitamin D level above 33 ng/m increases the success of bone drug density drug therapy seven-fold.The study is the first to formally examin vitamin D levels and outcomes for improving bone mineral density and loss with the use of the FDA approved...

More Zometa News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo